Company Overview of Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma. Its lead product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye’s natural pressure control mechanism. The company is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals Corporation was founded in 1999 and ...
131 Hartwell Avenue
Lexington, MA 02421
Founded in 1999
Key Executives for Inotek Pharmaceuticals Corporation
Vice President of Finance
Chief Scientific Officer and Executive Vice President
Chief Medical Officer and Executive Vice President
Compensation as of Fiscal Year 2014.
Inotek Pharmaceuticals Corporation Key Developments
Inotek Pharmaceuticals, Inc. Appoints David. P. Southwell as President, Chief Executive Officer and to its Board
Aug 13 14
Inotek Pharmaceuticals Inc. announced that David. P. Southwell has been named President and Chief Executive Officer. Mr. Southwell will also join the Board of Directors. Mr. Southwell brings to Inotek more than 20 years of experience in biotechnology and pharmaceuticals including financings, mergers and acquisitions, and general corporate leadership. Prior to joining Inotek, Mr. Southwell served as Executive Vice President and Chief Financial Officer of Human Genome Sciences during the approval and launch of Benlysta(R). He currently serves on the boards of PTC Therapeutics and THL Credit Inc. and on the Board of Overseers of the Tuck School of Business at Dartmouth College.
Inotek Pharmaceuticals Announces Study Results Demonstrating Neuroprotective Properties of Trabodenoson
May 30 14
Inotek Pharmaceuticals Corporation announced the results from a preclinical study demonstrating the ability of trabodenoson, an adenosine A1 mimetic in development for glaucoma, to protect against the loss of retinal ganglion cells in an acute high-ocular-pressure animal model of glaucoma. Retinal ganglion cells are the part of the nervous system responsible for relaying the visual image from the eye to the brain, and their death is what causes the irreversible vision loss associated with glaucoma. The results of this study were presented this month at the 2014 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). This preclinical neuroprotection study was designed to compare the protective effects of trabodenoson and brimonidine in a rat model of ischemia-induced retinal ganglion cell (RGC) death. Trabodenoson was delivered as an eye drop at a clinically relevant dose. Results of the study showed that trabodenoson provided 100% protection against the thinning of the ganglion cell layer (p<=0.001 compared to vehicle-treated eyes).
Inotek Pharmaceuticals Initiates Phase 2 Study with Trabodenoson in Combination with Latanoprost for Patients with Glaucoma or Ocular Hypertension
Mar 10 14
Inotek Pharmaceuticals Inc. announced the initiation of a Phase 2 clinical study of its lead product, trabodenoson, in combination with the most widely-prescribed glaucoma drug, the prostaglandin analog latanoprost (LAT), in patients with elevated intraocular pressure (IOP) that remains uncontrolled despite ongoing treatment with latanoprost. The Phase 2 study is a randomized, double-masked, active-controlled, multicenter trial comparing trabodenoson plus LAT, to timolol (the active comparator) plus LAT, in 120 patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG). The study will measure the additive or synergistic IOP lowering effect of trabodenoson when combined with LAT, and will also evaluate the safety and tolerability of the combined treatment regimen. The total treatment time will be 3 months, during which the effect of trabodenoson will be evaluated following twice-a-day dosing (BID) and once-daily dosing (QD). Top line data is expected in the fourth quarter of 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|